Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer

Background Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin‐targeted immunotherapies are currently under way...

Full description

Saved in:
Bibliographic Details
Published inThe oncologist (Dayton, Ohio) Vol. 24; no. 11; pp. e1108 - e1114
Main Authors Shin, Su‐Jin, Park, Sejung, Kim, Min Hwan, Nam, Chung Mo, Kim, Hyunki, Choi, Yoon Young, Jung, Min Kyu, Choi, Hye Jin, Rha, Sun Young, Chung, Hyun Cheol
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.11.2019
Subjects
Online AccessGet full text
ISSN1083-7159
1549-490X
1549-490X
DOI10.1634/theoncologist.2018-0896

Cover

Abstract Background Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin‐targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear. Subjects, Materials, and Methods Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence‐free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition. Results High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010). Conclusion High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer. Implications for Practice This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti‐mesothelin antibody‐drug conjugate clinical trials in patients with diffuse‐type gastric cancer to reduce their high risk of peritoneal carcinomatosis. 摘要 背景。间皮素在很多实体肿瘤中会过度表达,近期研究表明,间皮素表达与若干恶性肿瘤的预后不良有关,并且可能在癌症进展过程中起到一定的作用。尽管目前正在进行以间皮素为靶标的免疫疗法的临床试验,但是间皮素表达与胃癌预后之间的相关性尚不明确。 对象、材料和方法。我们对 958 例晚期胃癌患者的癌细胞间皮素表达进行了免疫组织化学评估,并根据染色的强度和程度进行了解释。样本得分为 0 到 2 分,而 2 分则定义为高表达。我们还评估了临床病理因素、总生存期 (OS)、无复发生存期 (RFS) 和初次复发部位,包括腹膜复发。根据美国癌症联合委员会第 7 版进行分期。 结果。在 49.7% 的患者中观察到间皮素高表达,且该间皮素高表达与较高的病理性 T (p = 0.021) 以及腹膜复发 (p = 0.018) 显著相关。多因素生存分析表明,除了分期、淋巴血管浸润和 Lauren 分类之外,间皮素高表达还与不良 RFS (p = 0.001)、OS (p = 0.001) 以及腹膜复发 (p = 0.002) 等因素独立相关。腹膜复发的亚组分析表明,间皮素高表达也是 III 期 (p = 0.013) 和弥漫型/混合型胃癌 (p = 0.010) 的独立预后因素。 结论。间皮素高表达与预后不良相关。此外,间皮素表达、Lauren 分类和分期对腹膜复发而言是意义重大的预测因素。而且,间皮素是 III 期胃癌患者腹膜复发高风险的重要预测因素。 实践意义:本研究表明,间皮素高表达与预后不良相关,并且是 III 期胃癌患者腹膜复发的重要预测因素。本研究为设计弥漫型胃癌患者的抗‐间皮素抗体‐药物偶联物临床试验,从而降低腹膜转移的高风险提供了有效证据。 This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its prognostic significance and association with clinicopathological factors in gastric cancer.
AbstractList This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its prognostic significance and association with clinicopathological factors in gastric cancer.
Background Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin‐targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear. Subjects, Materials, and Methods Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence‐free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition. Results High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010). Conclusion High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer. Implications for Practice This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti‐mesothelin antibody‐drug conjugate clinical trials in patients with diffuse‐type gastric cancer to reduce their high risk of peritoneal carcinomatosis. 摘要 背景。间皮素在很多实体肿瘤中会过度表达,近期研究表明,间皮素表达与若干恶性肿瘤的预后不良有关,并且可能在癌症进展过程中起到一定的作用。尽管目前正在进行以间皮素为靶标的免疫疗法的临床试验,但是间皮素表达与胃癌预后之间的相关性尚不明确。 对象、材料和方法。我们对 958 例晚期胃癌患者的癌细胞间皮素表达进行了免疫组织化学评估,并根据染色的强度和程度进行了解释。样本得分为 0 到 2 分,而 2 分则定义为高表达。我们还评估了临床病理因素、总生存期 (OS)、无复发生存期 (RFS) 和初次复发部位,包括腹膜复发。根据美国癌症联合委员会第 7 版进行分期。 结果。在 49.7% 的患者中观察到间皮素高表达,且该间皮素高表达与较高的病理性 T (p = 0.021) 以及腹膜复发 (p = 0.018) 显著相关。多因素生存分析表明,除了分期、淋巴血管浸润和 Lauren 分类之外,间皮素高表达还与不良 RFS (p = 0.001)、OS (p = 0.001) 以及腹膜复发 (p = 0.002) 等因素独立相关。腹膜复发的亚组分析表明,间皮素高表达也是 III 期 (p = 0.013) 和弥漫型/混合型胃癌 (p = 0.010) 的独立预后因素。 结论。间皮素高表达与预后不良相关。此外,间皮素表达、Lauren 分类和分期对腹膜复发而言是意义重大的预测因素。而且,间皮素是 III 期胃癌患者腹膜复发高风险的重要预测因素。 实践意义:本研究表明,间皮素高表达与预后不良相关,并且是 III 期胃癌患者腹膜复发的重要预测因素。本研究为设计弥漫型胃癌患者的抗‐间皮素抗体‐药物偶联物临床试验,从而降低腹膜转移的高风险提供了有效证据。 This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its prognostic significance and association with clinicopathological factors in gastric cancer.
Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin-targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear. Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence-free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition. High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T ( = .021) and peritoneal recurrence ( = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS ( = .001), OS ( = .001), and peritoneal recurrence ( = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III ( = .013) and diffuse/mixed type gastric cancer ( = .010). High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer. This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti-mesothelin antibody-drug conjugate clinical trials in patients with diffuse-type gastric cancer to reduce their high risk of peritoneal carcinomatosis.
Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin-targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear.BACKGROUNDMesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several malignant tumors and may play a role in cancer progression. Clinical trials of mesothelin-targeted immunotherapies are currently under way, but the correlation between mesothelin expression and gastric cancer prognosis is still unclear.Mesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence-free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition.SUBJECTS, MATERIALS, AND METHODSMesothelin expression in tumor cells was evaluated immunohistochemically in 958 patients with advanced gastric cancer and interpreted according to the intensity and extent of staining. Samples were scored from 0 to 2, with high expression defined as a score of 2. Clinicopathological factors, overall survival (OS), recurrence-free survival (RFS), and sites of initial recurrence, including peritoneal recurrence, were evaluated. Staging was performed according to the American Joint Committee on Cancer 7th edition.High mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010).RESULTSHigh mesothelin expression was observed in 49.7% of patients and significantly associated with high pathologic T (p = .021) and peritoneal recurrence (p = .018). Multivariate survival analysis showed that high mesothelin expression was independently associated with poor RFS (p = .001), OS (p = .001), and peritoneal recurrence (p = .002) in addition to stage, lymphovascular invasion, and Lauren classification. In a subgroup analysis of peritoneal recurrence, high mesothelin expression was also an independent prognostic factor in stage III (p = .013) and diffuse/mixed type gastric cancer (p = .010).High mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer.CONCLUSIONHigh mesothelin expression is correlated with poor outcomes. In addition, mesothelin expression, Lauren classification, and stage are meaningful predictive factors for peritoneal recurrence. Moreover, mesothelin was a significant predictor of a high risk of peritoneal recurrence in patients with stage III gastric cancer.This study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti-mesothelin antibody-drug conjugate clinical trials in patients with diffuse-type gastric cancer to reduce their high risk of peritoneal carcinomatosis.IMPLICATIONS FOR PRACTICEThis study demonstrates that high mesothelin expression correlates with poor outcomes and is a significant predictor of peritoneal recurrence in patients with stage III gastric cancer. This study provides instrumental evidence for designing anti-mesothelin antibody-drug conjugate clinical trials in patients with diffuse-type gastric cancer to reduce their high risk of peritoneal carcinomatosis.
Author Kim, Hyunki
Choi, Yoon Young
Choi, Hye Jin
Chung, Hyun Cheol
Nam, Chung Mo
Shin, Su‐Jin
Jung, Min Kyu
Rha, Sun Young
Park, Sejung
Kim, Min Hwan
Author_xml – sequence: 1
  givenname: Su‐Jin
  orcidid: 0000-0001-9114-8438
  surname: Shin
  fullname: Shin, Su‐Jin
  organization: Department of Pathology, College of Medicine, Hanyang University
– sequence: 2
  givenname: Sejung
  surname: Park
  fullname: Park, Sejung
  organization: Department of Biostatistics, Yonsei University College of Medicine
– sequence: 3
  givenname: Min Hwan
  surname: Kim
  fullname: Kim, Min Hwan
  organization: Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine
– sequence: 4
  givenname: Chung Mo
  surname: Nam
  fullname: Nam, Chung Mo
  organization: Department of Preventive Medicine, Yonsei University College of Medicine
– sequence: 5
  givenname: Hyunki
  surname: Kim
  fullname: Kim, Hyunki
  organization: Department of Pathology, Yonsei University College of Medicine
– sequence: 6
  givenname: Yoon Young
  surname: Choi
  fullname: Choi, Yoon Young
  organization: Department of Surgery, Yonsei University College of Medicine
– sequence: 7
  givenname: Min Kyu
  surname: Jung
  fullname: Jung, Min Kyu
  organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine
– sequence: 8
  givenname: Hye Jin
  surname: Choi
  fullname: Choi, Hye Jin
  organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine
– sequence: 9
  givenname: Sun Young
  surname: Rha
  fullname: Rha, Sun Young
  organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine
– sequence: 10
  givenname: Hyun Cheol
  orcidid: 0000-0002-0920-9471
  surname: Chung
  fullname: Chung, Hyun Cheol
  email: unchung8@yuhs.ac
  organization: Cancer Metastasis Research Center, Song Dang Institute for Cancer Research, Yonsei University College of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31015316$$D View this record in MEDLINE/PubMed
BookMark eNqVUdtuFCEYJqbGHvQVlEtvpsIwB7jQxEzaOkl1Gw-Jd4Rh_t1iWNgCs3XfXsath3pVLwg_-U7wcYwOnHeA0AtKTmnDqlfpGrzT3vqViem0JJQXhIvmETqidSWKSpCvB3kmnBUtrcUhOo7xGyF5ZOUTdMhoHhltjtD2PUSf3axx-Oz7JkCMxjvcR6zwVYDR6GS2gM-VTj7gZV5XEEzKt1EWfwQ9hQBOA87ybgpqJttdBiLoBCP-lNQKcN_3-ELFFIzGncr08BQ9Xiob4dndfoK-nJ997t4Vl4uLvnt7WeiacVoIpglhLeNNJRSwpq5H0AJGzdrlwBVlnCx1PikYS6q04JTrjBE9DHTgtGQniO99J7dRu1tlrdwEs1ZhJymRc5XyXpVyrlLOVWbpm710Mw3rHAkuBfVH7pWR9xFnruXKb2XDc7U_s1_eGQR_M0E2X5uowVrlwE9RliVlgraVoJn6_O-s3yG__ikTXu8JOvgYAyylNim37edoYx_wmPYf_X_XcGss7B4qk4sP3YKWoqbsB0hA2fk
CitedBy_id crossref_primary_10_3390_biomedicines9040397
crossref_primary_10_1016_j_ajpath_2024_07_009
crossref_primary_10_1158_1541_7786_MCR_19_0688
crossref_primary_10_1002_ags3_12565
crossref_primary_10_1016_j_adcanc_2023_100098
crossref_primary_10_1038_s41434_023_00388_z
crossref_primary_10_3390_cancers12082236
crossref_primary_10_1007_s12672_024_01159_x
crossref_primary_10_3389_fonc_2021_781800
crossref_primary_10_3389_fvets_2024_1436621
crossref_primary_10_4251_wjgo_v14_i1_90
crossref_primary_10_1200_JCO_21_02745
crossref_primary_10_3390_jcm9061894
crossref_primary_10_1159_000526333
crossref_primary_10_1007_s11912_023_01367_8
crossref_primary_10_2217_imt_2021_0285
crossref_primary_10_1007_s10555_020_09924_4
crossref_primary_10_3390_biom10070973
Cites_doi 10.1158/1055-9965.EPI-11-0993
10.2174/1871520611313020014
10.1111/j.0006-341X.2005.030814.x
10.1128/MCB.20.8.2902-2906.2000
10.1007/s13277-015-3304-7
10.1186/s12957-016-1042-y
10.1016/S1470-2045(14)70473-5
10.1038/bjc.2012.235
10.1002/jso.22024
10.1158/0008-5472.CAN-14-0337
10.1007/s00268-010-0573-6
10.1097/SLA.0000000000002040
10.18632/oncotarget.4461
10.1007/PL00011698
10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
10.1002/sim.6428
10.3322/caac.21262
10.1016/S0140-6736(11)61873-4
10.1371/journal.pone.0114900
10.1016/j.ejso.2010.09.006
10.1111/apm.1965.64.1.31
10.1158/1078-0432.CCR-13-1862
10.1038/srep01870
10.1158/1078-0432.CCR-11-2614
10.1038/nature13480
10.1002/cncr.22317
10.3748/wjg.v22.i30.6829
10.1158/2159-8290.CD-15-0583
10.1089/gtmb.2017.0060
10.1074/jbc.M312372200
ContentType Journal Article
Copyright AlphaMed Press 2019
AlphaMed Press 2019.
Copyright_xml – notice: AlphaMed Press 2019
– notice: AlphaMed Press 2019.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
ADTOC
UNPAY
DOI 10.1634/theoncologist.2018-0896
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
Unpaywall for CDI: Periodical Content
Unpaywall
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList

MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: UNPAY
  name: Unpaywall
  url: https://proxy.k.utb.cz/login?url=https://unpaywall.org/
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1549-490X
EndPage e1114
ExternalDocumentID 10.1634/theoncologist.2018-0896
PMC6853112
31015316
10_1634_theoncologist_2018_0896
ONCO12951
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
0R~
123
18M
1OC
24P
2WC
36B
4.4
53G
5VS
AAPXW
AAVAP
AAWTL
AAZKR
ABEJV
ABPTD
ABXVV
ACXQS
ADBBV
ADXAS
AEGXH
AENEX
AJAOE
ALMA_UNASSIGNED_HOLDINGS
AMNDL
AOIJS
BAWUL
BFHJK
CS3
DCZOG
DIK
DU5
E3Z
EBD
EBS
EJD
EMB
EMOBN
F5P
FRP
GROUPED_DOAJ
GX1
H13
HYE
HZ~
IAO
IHR
INH
ITC
LUTES
LYRES
O9-
OK1
P2P
P2W
RAO
RHF
RHI
ROL
ROX
RPM
SUPJJ
SV3
TOX
TR2
UDS
W2D
W8F
WIN
WOHZO
WOQ
WOW
XSB
ZZTAW
AAFWJ
AAMMB
AAYXX
ABGNP
AEFGJ
AFPKN
AGXDD
AIDQK
AIDYY
CITATION
OVT
7X7
88E
8FI
8FJ
ABUWG
AFKRA
BENPR
CCPQU
CGR
CUY
CVF
ECM
EIF
FYUFA
HMCUK
M1P
NPM
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PSQYO
UKHRP
7X8
5PM
ADTOC
UNPAY
ID FETCH-LOGICAL-c5381-93c003738649ae3655dec9edc37fb8a1380fcdc3aed21ac9818cc370cbb1b8123
IEDL.DBID UNPAY
ISSN 1083-7159
1549-490X
IngestDate Tue Aug 19 17:23:44 EDT 2025
Thu Aug 21 18:03:26 EDT 2025
Wed Oct 01 12:55:13 EDT 2025
Mon Jul 21 05:56:58 EDT 2025
Thu Apr 24 22:55:48 EDT 2025
Wed Oct 01 02:01:44 EDT 2025
Wed Jan 22 16:38:56 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords Mesothelin
Stomach cancer
Survival
Peritoneal recurrence
Prediction
Language English
License https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model
AlphaMed Press 2019.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5381-93c003738649ae3655dec9edc37fb8a1380fcdc3aed21ac9818cc370cbb1b8123
Notes .
Disclosures of potential conflicts of interest may be found at the end of this article
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Disclosures of potential conflicts of interest may be found at the end of this article.
ORCID 0000-0002-0920-9471
0000-0001-9114-8438
OpenAccessLink https://proxy.k.utb.cz/login?url=https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0896
PMID 31015316
PQID 2213917491
PQPubID 23479
PageCount 7
ParticipantIDs unpaywall_primary_10_1634_theoncologist_2018_0896
pubmedcentral_primary_oai_pubmedcentral_nih_gov_6853112
proquest_miscellaneous_2213917491
pubmed_primary_31015316
crossref_citationtrail_10_1634_theoncologist_2018_0896
crossref_primary_10_1634_theoncologist_2018_0896
wiley_primary_10_1634_theoncologist_2018_0896_ONCO12951
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate November 2019
PublicationDateYYYYMMDD 2019-11-01
PublicationDate_xml – month: 11
  year: 2019
  text: November 2019
PublicationDecade 2010
PublicationPlace Hoboken, USA
PublicationPlace_xml – name: Hoboken, USA
– name: England
PublicationTitle The oncologist (Dayton, Ohio)
PublicationTitleAlternate Oncologist
PublicationYear 2019
Publisher John Wiley & Sons, Inc
Publisher_xml – name: John Wiley & Sons, Inc
References 2010; 34
2015; 34
2015; 36
2014; 513
2013; 3
2015; 6
2010; 36
2010
2000; 3
2018; 267
2017; 21
2000; 20
2012; 18
2005; 61
2012; 105
1996; 15
2016; 14
2012; 107
2016; 34
2014; 20
1992; 52
2016; 6
1965; 64
2004; 279
2013; 13
2015; 65
2014; 15
2014; 9
2014; 74
2012; 379
2006; 107
2012; 21
2016; 22
Torre (2021122508114463600_onco12951-bib-0001) 2015; 65
Yonemura (2021122508114463600_onco12951-bib-0030) 2000; 3
Lauren (2021122508114463600_onco12951-bib-0020) 1965; 64
Demler (2021122508114463600_onco12951-bib-0019) 2015; 34
Tang (2021122508114463600_onco12951-bib-0010) 2013; 13
Pastan (2021122508114463600_onco12951-bib-0033) 2014; 74
Bilici (2021122508114463600_onco12951-bib-0006) 2015; 36
Yonemura (2021122508114463600_onco12951-bib-0007) 2010; 36
Noh (2021122508114463600_onco12951-bib-0004) 2014; 15
Heagerty (2021122508114463600_onco12951-bib-0018) 2005; 61
Rizk (2021122508114463600_onco12951-bib-0026) 2012; 21
Cancer Genome Atlas Research Network (2021122508114463600_onco12951-bib-0021) 2014; 513
Kanda (2021122508114463600_onco12951-bib-0022) 2016; 22
Servais (2021122508114463600_onco12951-bib-0012) 2012; 18
Lee (2021122508114463600_onco12951-bib-0023) 2018; 267
Chen (2021122508114463600_onco12951-bib-0028) 2013; 3
Zeng (2021122508114463600_onco12951-bib-0009) 2017; 21
Rump (2021122508114463600_onco12951-bib-0029) 2004; 279
Baba (2021122508114463600_onco12951-bib-0015) 2012; 105
Rohatgi (2021122508114463600_onco12951-bib-0003) 2006; 107
Bera (2021122508114463600_onco12951-bib-0024) 2000; 20
Lamberts (2021122508114463600_onco12951-bib-0032) 2015; 6
Blumenschein (2021122508114463600_onco12951-bib-0014) 2016; 34
Morello (2021122508114463600_onco12951-bib-0011) 2016; 6
Tozbikian (2021122508114463600_onco12951-bib-0027) 2014; 9
Edge (2021122508114463600_onco12951-bib-0016) 2010
Harrell (2021122508114463600_onco12951-bib-0017) 1996; 15
Kachala (2021122508114463600_onco12951-bib-0025) 2014; 20
Bang (2021122508114463600_onco12951-bib-0002) 2012; 379
Chang (2021122508114463600_onco12951-bib-0031) 1992; 52
Einama (2021122508114463600_onco12951-bib-0013) 2012; 107
Liu (2021122508114463600_onco12951-bib-0005) 2016; 14
Ito (2021122508114463600_onco12951-bib-0008) 2010; 34
References_xml – volume: 379
  start-page: 315
  year: 2012
  end-page: 321
  article-title: Adjuvant capecitabine and oxaliplatin for gastric cancer after d2 gastrectomy (classic): A phase 3 open‐label, randomised controlled trial
  publication-title: Lancet
– volume: 3
  start-page: 63
  year: 2000
  end-page: 70
  article-title: Role of MMP‐7 in the formation of peritoneal dissemination in gastric cancer
  publication-title: Gastric Cancer
– volume: 61
  start-page: 92
  year: 2005
  end-page: 105
  article-title: Survival model predictive accuracy and ROC curves
  publication-title: Biometrics
– volume: 36
  start-page: 6191
  year: 2015
  end-page: 6199
  article-title: Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy
  publication-title: Tumour Biol
– volume: 65
  start-page: 87
  year: 2015
  end-page: 108
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J Clin
– volume: 21
  start-page: 482
  year: 2012
  end-page: 486
  article-title: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 3
  start-page: 1870
  year: 2013
  article-title: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP‐7 activation
  publication-title: Sci Rep
– volume: 52
  start-page: 181
  year: 1992
  end-page: 186
  article-title: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium
  publication-title: Cancer Res
– volume: 34
  issue: suppl 15
  year: 2016
  article-title: Phase I study of anti‐mesothelin antibody drug conjugate anetumab ravtansine (AR)
  publication-title: J Clin Oncol
– volume: 22
  start-page: 6829
  year: 2016
  end-page: 6840
  article-title: Molecular mechanisms of peritoneal dissemination in gastric cancer
  publication-title: World J Gastroenterol
– volume: 18
  start-page: 2478
  year: 2012
  end-page: 2489
  article-title: Mesothelin overexpression promotes mesothelioma cell invasion and MMP‐9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients
  publication-title: Clin Cancer Res
– volume: 74
  start-page: 2907
  year: 2014
  end-page: 2912
  article-title: Discovery of mesothelin and exploiting it as a target for immunotherapy
  publication-title: Cancer Res
– volume: 6
  start-page: 28164
  year: 2015
  end-page: 28172
  article-title: Functional genomic mrna profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types
  publication-title: Oncotarget
– volume: 36
  start-page: 1131
  year: 2010
  end-page: 1138
  article-title: Surgical treatment for peritoneal carcinomatosis from gastric cancer
  publication-title: Eur J Surg Oncol
– volume: 34
  start-page: 2083
  year: 2010
  end-page: 2089
  article-title: Phase II clinical trial of postoperative S‐1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real‐time RT‐PCR
  publication-title: World J Surg
– year: 2010
– volume: 13
  start-page: 276
  year: 2013
  end-page: 280
  article-title: The role of mesothelin in tumor progression and targeted therapy
  publication-title: Anticancer Agents Med Chem
– volume: 21
  start-page: 641
  year: 2017
  end-page: 648
  article-title: Lysophosphatidic acid is a biomarker for peritoneal carcinomatosis of gastric cancer and correlates with poor prognosis
  publication-title: Genet Test Mol Biomarkers
– volume: 513
  start-page: 202
  year: 2014
  end-page: 209
  article-title: Comprehensive molecular characterization of gastric adenocarcinoma
  publication-title: Nature
– volume: 34
  start-page: 1659
  year: 2015
  end-page: 1680
  article-title: Tests of calibration and goodness‐of‐fit in the survival setting
  publication-title: Stat Med
– volume: 6
  start-page: 133
  year: 2016
  end-page: 146
  article-title: Mesothelin‐targeted cars: Driving T cells to solid tumors
  publication-title: Cancer Discov
– volume: 14
  start-page: 305
  year: 2016
  article-title: The patterns and timing of recurrence after curative resection for gastric cancer in China
  publication-title: World J Surg Oncol
– volume: 279
  start-page: 9190
  year: 2004
  end-page: 9198
  article-title: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
  publication-title: J Biol Chem
– volume: 267
  start-page: 105
  year: 2018
  end-page: 113
  article-title: Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma
  publication-title: Ann Surg
– volume: 64
  start-page: 31
  year: 1965
  end-page: 49
  article-title: The two histological main types of gastric carcinoma: Diffuse and so‐called intestinal‐type carcinoma. An attempt at a histo‐clinical classification
  publication-title: Acta Pathol Microbiol Scand
– volume: 20
  start-page: 2902
  year: 2000
  end-page: 2906
  article-title: Mesothelin is not required for normal mouse development or reproduction
  publication-title: Mol Cell Biol
– volume: 15
  start-page: 361
  year: 1996
  end-page: 387
  article-title: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
  publication-title: Stat Med
– volume: 15
  start-page: 1389
  year: 2014
  end-page: 1396
  article-title: Adjuvant capecitabine plus oxaliplatin for gastric cancer after d2 gastrectomy (classic): 5‐year follow‐up of an open‐label, randomised phase 3 trial
  publication-title: Lancet Oncol
– volume: 107
  start-page: 137
  year: 2012
  end-page: 142
  article-title: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
  publication-title: Br J Cancer
– volume: 9
  year: 2014
  article-title: Mesothelin expression in triple negative breast carcinomas correlates significantly with basal‐like phenotype, distant metastases and decreased survival
  publication-title: PLoS One
– volume: 107
  start-page: 2576
  year: 2006
  end-page: 2580
  article-title: Outcome of gastric cancer patients after successful gastrectomy: Influence of the type of recurrence and histology on survival
  publication-title: Cancer
– volume: 105
  start-page: 195
  year: 2012
  end-page: 199
  article-title: Mesothelin expression correlates with prolonged patient survival in gastric cancer
  publication-title: J Surg Oncol
– volume: 20
  start-page: 1020
  year: 2014
  end-page: 1028
  article-title: Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence‐free and overall survival in early‐stage lung adenocarcinoma
  publication-title: Clin Cancer Res
– volume: 21
  start-page: 482
  year: 2012
  ident: 2021122508114463600_onco12951-bib-0026
  article-title: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-11-0993
– volume: 13
  start-page: 276
  year: 2013
  ident: 2021122508114463600_onco12951-bib-0010
  article-title: The role of mesothelin in tumor progression and targeted therapy
  publication-title: Anticancer Agents Med Chem
  doi: 10.2174/1871520611313020014
– volume: 61
  start-page: 92
  year: 2005
  ident: 2021122508114463600_onco12951-bib-0018
  article-title: Survival model predictive accuracy and ROC curves
  publication-title: Biometrics
  doi: 10.1111/j.0006-341X.2005.030814.x
– volume: 20
  start-page: 2902
  year: 2000
  ident: 2021122508114463600_onco12951-bib-0024
  article-title: Mesothelin is not required for normal mouse development or reproduction
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.20.8.2902-2906.2000
– volume: 36
  start-page: 6191
  year: 2015
  ident: 2021122508114463600_onco12951-bib-0006
  article-title: Prognostic significance of the recurrence pattern and risk factors for recurrence in patients with proximal gastric cancer who underwent curative gastrectomy
  publication-title: Tumour Biol
  doi: 10.1007/s13277-015-3304-7
– volume: 14
  start-page: 305
  year: 2016
  ident: 2021122508114463600_onco12951-bib-0005
  article-title: The patterns and timing of recurrence after curative resection for gastric cancer in China
  publication-title: World J Surg Oncol
  doi: 10.1186/s12957-016-1042-y
– volume: 15
  start-page: 1389
  year: 2014
  ident: 2021122508114463600_onco12951-bib-0004
  article-title: Adjuvant capecitabine plus oxaliplatin for gastric cancer after d2 gastrectomy (classic): 5-year follow-up of an open-label, randomised phase 3 trial
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(14)70473-5
– volume: 107
  start-page: 137
  year: 2012
  ident: 2021122508114463600_onco12951-bib-0013
  article-title: Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer
  publication-title: Br J Cancer
  doi: 10.1038/bjc.2012.235
– volume: 105
  start-page: 195
  year: 2012
  ident: 2021122508114463600_onco12951-bib-0015
  article-title: Mesothelin expression correlates with prolonged patient survival in gastric cancer
  publication-title: J Surg Oncol
  doi: 10.1002/jso.22024
– volume: 74
  start-page: 2907
  year: 2014
  ident: 2021122508114463600_onco12951-bib-0033
  article-title: Discovery of mesothelin and exploiting it as a target for immunotherapy
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-14-0337
– volume: 34
  start-page: 2083
  year: 2010
  ident: 2021122508114463600_onco12951-bib-0008
  article-title: Phase II clinical trial of postoperative S-1 monotherapy for gastric cancer patients with free intraperitoneal cancer cells detected by real-time RT-PCR
  publication-title: World J Surg
  doi: 10.1007/s00268-010-0573-6
– volume: 267
  start-page: 105
  year: 2018
  ident: 2021122508114463600_onco12951-bib-0023
  article-title: Lauren histologic type is the most important factor associated with pattern of recurrence following resection of gastric adenocarcinoma
  publication-title: Ann Surg
  doi: 10.1097/SLA.0000000000002040
– volume: 6
  start-page: 28164
  year: 2015
  ident: 2021122508114463600_onco12951-bib-0032
  article-title: Functional genomic mrna profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.4461
– volume: 3
  start-page: 63
  year: 2000
  ident: 2021122508114463600_onco12951-bib-0030
  article-title: Role of MMP-7 in the formation of peritoneal dissemination in gastric cancer
  publication-title: Gastric Cancer
  doi: 10.1007/PL00011698
– volume: 15
  start-page: 361
  year: 1996
  ident: 2021122508114463600_onco12951-bib-0017
  article-title: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors
  publication-title: Stat Med
  doi: 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
– volume: 34
  start-page: 1659
  year: 2015
  ident: 2021122508114463600_onco12951-bib-0019
  article-title: Tests of calibration and goodness-of-fit in the survival setting
  publication-title: Stat Med
  doi: 10.1002/sim.6428
– volume: 65
  start-page: 87
  year: 2015
  ident: 2021122508114463600_onco12951-bib-0001
  article-title: Global cancer statistics, 2012
  publication-title: CA Cancer J Clin
  doi: 10.3322/caac.21262
– volume: 379
  start-page: 315
  year: 2012
  ident: 2021122508114463600_onco12951-bib-0002
  article-title: Adjuvant capecitabine and oxaliplatin for gastric cancer after d2 gastrectomy (classic): A phase 3 open-label, randomised controlled trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(11)61873-4
– volume: 9
  year: 2014
  ident: 2021122508114463600_onco12951-bib-0027
  article-title: Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0114900
– volume: 34
  issue: suppl 15
  year: 2016
  ident: 2021122508114463600_onco12951-bib-0014
  article-title: Phase I study of anti-mesothelin antibody drug conjugate anetumab ravtansine (AR)
  publication-title: J Clin Oncol
– volume-title: American Joint Committee on Cancer. AJCC Cancer Staging Manual
  year: 2010
  ident: 2021122508114463600_onco12951-bib-0016
– volume: 36
  start-page: 1131
  year: 2010
  ident: 2021122508114463600_onco12951-bib-0007
  article-title: Surgical treatment for peritoneal carcinomatosis from gastric cancer
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2010.09.006
– volume: 64
  start-page: 31
  year: 1965
  ident: 2021122508114463600_onco12951-bib-0020
  article-title: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification
  publication-title: Acta Pathol Microbiol Scand
  doi: 10.1111/apm.1965.64.1.31
– volume: 20
  start-page: 1020
  year: 2014
  ident: 2021122508114463600_onco12951-bib-0025
  article-title: Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-13-1862
– volume: 3
  start-page: 1870
  year: 2013
  ident: 2021122508114463600_onco12951-bib-0028
  article-title: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation
  publication-title: Sci Rep
  doi: 10.1038/srep01870
– volume: 18
  start-page: 2478
  year: 2012
  ident: 2021122508114463600_onco12951-bib-0012
  article-title: Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-11-2614
– volume: 513
  start-page: 202
  year: 2014
  ident: 2021122508114463600_onco12951-bib-0021
  article-title: Comprehensive molecular characterization of gastric adenocarcinoma
  publication-title: Nature
  doi: 10.1038/nature13480
– volume: 107
  start-page: 2576
  year: 2006
  ident: 2021122508114463600_onco12951-bib-0003
  article-title: Outcome of gastric cancer patients after successful gastrectomy: Influence of the type of recurrence and histology on survival
  publication-title: Cancer
  doi: 10.1002/cncr.22317
– volume: 22
  start-page: 6829
  year: 2016
  ident: 2021122508114463600_onco12951-bib-0022
  article-title: Molecular mechanisms of peritoneal dissemination in gastric cancer
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v22.i30.6829
– volume: 6
  start-page: 133
  year: 2016
  ident: 2021122508114463600_onco12951-bib-0011
  article-title: Mesothelin-targeted cars: Driving T cells to solid tumors
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-15-0583
– volume: 21
  start-page: 641
  year: 2017
  ident: 2021122508114463600_onco12951-bib-0009
  article-title: Lysophosphatidic acid is a biomarker for peritoneal carcinomatosis of gastric cancer and correlates with poor prognosis
  publication-title: Genet Test Mol Biomarkers
  doi: 10.1089/gtmb.2017.0060
– volume: 279
  start-page: 9190
  year: 2004
  ident: 2021122508114463600_onco12951-bib-0029
  article-title: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M312372200
– volume: 52
  start-page: 181
  year: 1992
  ident: 2021122508114463600_onco12951-bib-0031
  article-title: Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium
  publication-title: Cancer Res
SSID ssj0015932
Score 2.405408
Snippet Background Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in...
Mesothelin is overexpressed in many solid tumors, and recent studies have shown that mesothelin expression is associated with poor outcomes in several...
This article examines mesothelin expression with a focus on its potential as a predictive biomarker of peritoneal recurrence after curative surgery and its...
SourceID unpaywall
pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e1108
SubjectTerms Adult
Aged
Aged, 80 and over
Biomarkers, Tumor - metabolism
Female
Gastrectomy
Gastrointestinal Cancer
GPI-Linked Proteins - metabolism
Humans
Male
Mesothelin
Middle Aged
Peritoneal Neoplasms - metabolism
Peritoneal Neoplasms - mortality
Peritoneal Neoplasms - secondary
Peritoneal recurrence
Prediction
Prognosis
Retrospective Studies
Risk
Stomach cancer
Stomach Neoplasms - metabolism
Stomach Neoplasms - mortality
Stomach Neoplasms - pathology
Stomach Neoplasms - surgery
Survival
Survival Analysis
Title Mesothelin Expression Is a Predictive Factor for Peritoneal Recurrence in Curatively Resected Stage III Gastric Cancer
URI https://onlinelibrary.wiley.com/doi/abs/10.1634%2Ftheoncologist.2018-0896
https://www.ncbi.nlm.nih.gov/pubmed/31015316
https://www.proquest.com/docview/2213917491
https://pubmed.ncbi.nlm.nih.gov/PMC6853112
https://theoncologist.onlinelibrary.wiley.com/doi/pdfdirect/10.1634/theoncologist.2018-0896
UnpaywallVersion publishedVersion
Volume 24
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVBFR
  databaseName: Free Medical Journals
  customDbUrl:
  eissn: 1549-490X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015932
  issn: 1549-490X
  databaseCode: DIK
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVFQY
  databaseName: GFMER Free Medical Journals
  customDbUrl:
  eissn: 1549-490X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015932
  issn: 1549-490X
  databaseCode: GX1
  dateStart: 0
  isFulltext: true
  titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php
  providerName: Geneva Foundation for Medical Education and Research
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1549-490X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015932
  issn: 1549-490X
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVASL
  databaseName: Open Access: Oxford University Press Open Journals
  customDbUrl:
  eissn: 1549-490X
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0015932
  issn: 1549-490X
  databaseCode: TOX
  dateStart: 19960101
  isFulltext: true
  titleUrlDefault: https://academic.oup.com/journals/
  providerName: Oxford University Press
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9swED_aFLa-7Htr9lE02KuLZdmy9VhCs2aQD0YDGXswsixvZcELSbytY3_87mTH4Ba2MtibjXWyc_md9LN19xPAmwQ5txBGeyIJQi9ETHjIErRHH81sInUROZ3u8USez8N3i2ixBx93tTBUvlc6veZLqjhwahHt5zeKEzd6U7iv8qIe9V3gSxFes8WZjbSXldyHA0mrTz04mE9mpx_qlHvhxdxtpUYaZV6o_EWT_fWHnrpz1w1CejOv8m5VrvTVd71cdrmvm7yG9-HX7mfXOStfTqptdmJ-XlOE_E9-eQD3GtLLTmuUPoQ9Wz6CO-NmWf8xfBvbDVWC4e3Y2Y8mNbdkow3TbLamZjQos6HbG4ghzWYzDBySEcde39OKgatZZGg-qGop8-UVo6RCg4SaIaH-ZNloNGJvNW1TYtiAsL5-AvPh2cXg3Gs2hPAMjsscUWRIL0ckMlTaChlFuTUK_S3iIks0F4lfGDzTNg-4NgrJiMFrvskyniGTEU-hV-KzHQGzcWJI3UwUOXamuEKU8izQmcn9WGVxH-Tur05No5ZOm3YsU3prQq-mHa-m5NWUvNoHvzVc1YIhfzd5vcNSisFNKza6tF-rTRoESNDxnVHxPjyrsdV2irwcZyuO1nEHdW0DEg7vXikvPzsBcYkcDXl2H3iLz9s_a-zgdtv26XQymCKnjPjzf7jbCzjEY1XXfr6E3nZd2VdIArfZMexfTBfHTUj_Bh67Y5c
linkProvider Unpaywall
linkToUnpaywall http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3fa9swED66FLa-dL-77Bca7NXFsmzZeiyhWTNIGsYCGXswsix3ZcELSbytpX9872TH4Ba2MtibjXWyc_lO-mzdfQJ4nyDnFsJoTyRB6IWICQ9Zgvboo5lNpC4ip9M9nsiTWfhxHs134Ou2FobK90qn13xOFQdOLaL9_EZx4kZvCvdlXtSjvgt8KcIbtjizkfaykvdgV9LqUw92Z5Pp0Zc65V54MXdbqZFGmRcqf95kf_2hp-7cdYuQ3s6rfFCVS33xSy8WXe7rJq_hQ7ja_uw6Z-X7YbXJDs3lDUXI_-SXR7DfkF52VKP0MezY8gncHzfL-k_h59iuqRIMb8eOfzepuSUbrZlm0xU1o0GZDd3eQAxpNpti4JCMOPb6iVYMXM0iQ_NBVUuZLy4YJRUaJNQMCfWZZaPRiH3QtE2JYQPC-uoZzIbHnwcnXrMhhGdwXOaIIkN6OSKRodJWyCjKrVHobxEXWaK5SPzC4Jm2ecC1UUhGDF7zTZbxDJmMeA69Ep_tBTAbJ4bUzUSRY2eKK0QpzwKdmdyPVRb3QW7_6tQ0aum0accipbcm9Gra8WpKXk3Jq33wW8NlLRjyd5N3WyylGNy0YqNL-6Nap0GABB3fGRXvw0GNrbZT5OU4W3G0jjuoaxuQcHj3Snn-zQmIS-RoyLP7wFt83v1ZYwe3u7ZPTyeDU-SUEX_5D3d7BXt4rOraz9fQ26wq-wZJ4CZ72wTzNc46Yns
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Mesothelin+Expression+Is+a+Predictive+Factor+for+Peritoneal+Recurrence+in+Curatively+Resected+Stage+III+Gastric+Cancer&rft.jtitle=The+oncologist+%28Dayton%2C+Ohio%29&rft.au=Shin%2C+Su-Jin&rft.au=Park%2C+Sejung&rft.au=Kim%2C+Min+Hwan&rft.au=Nam%2C+Chung+Mo&rft.date=2019-11-01&rft.eissn=1549-490X&rft.volume=24&rft.issue=11&rft.spage=e1108&rft_id=info:doi/10.1634%2Ftheoncologist.2018-0896&rft_id=info%3Apmid%2F31015316&rft.externalDocID=31015316
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1083-7159&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1083-7159&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1083-7159&client=summon